As we move into 2026, the Company is equipped with numerous Phase 2 Catalysts and an AI-driven approach to drug development. Additionally, there is regulatory flexibility as we near the database lock, topline clinical data disclosure, and preparation for potential partnerships in relation to the SKNJCT-003 study.